Skip to main content
Fig. 2 | Pediatric Rheumatology

Fig. 2

From: Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance

Fig. 2

Ranking of biologics. Respondents were asked to rank the above biologic therapies in order of preference from 1 (first preference) to 5 (last preference). By weighted average, respondents favored rituximab (1.45) followed by abatacept (2.42), tocilizumab (3.07), infliximab (3.08), and other (3.77)

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096